Efficacy of Personalized Irradiation with Rhenium/Yttrium-Skin Cancer Therapy (SCT) for the Treatment of Non-Melanoma Skin Cancer

Boushehr University of Medical Sciences0 个研究点目标入组 20 人开始时间: 待定最近更新: 2023年5月29日

试验速览

暂无简介。

•Age >=18 years
•Stage I or II BCC (Basal Cell Carcinoma) or SCC (Squamous Cell Carcinoma)
•Confirmed Histology (with depth of lesion noted)
•Subjects with up to 3 lesions suitable to enter the study (subjects with more than 3 lesions are not excluded from the study, however 3 target lesions are determined for study evaluation only.)
•Subjects able and willing to comply with the requirements of the study
•Lesions with a depth up to 3mm confirmed on biopsy report AND deemed appropriate clinically by treating clinician
•Subjects who are not deemed suitable for surgery, for example due to tumour location, performance status or other comorbidities as deemed relevant by the treating clinician
•Patients who may have declined Surgery and/or fractionated Radiation Therapy

•Inability to personally provide written informed consent or to understand and collaborate throughout the study
•Inability or unwillingness to comply with study requirements
•Prior treatment with surgery or radiation therapy for their target lesion(s)
•Depth of lesion greater than 3mm as defined by Biopsy and/or clinical assessment
•Lupus and Scleroderma
•Prior laser at the tumour site
•Malignant melanoma systemic therapy ongoing
•Any ongoing treatment for malignancy, or in the last 4 weeks prior to study entry
•A tumour affecting nerves or bony structures
•pregnancy's and/or Lactation
•Anatomical exclusions: NMSC's of the Medial canthus, eyelid margin (upper and lower), Vermillion lip

发起方

Boushehr University of Medical Sciences